Homology Medicines Inc To Host Emerging Therapies and Clinical Trials Event Transcript
Good afternoon, everybody, and welcome to the National PKU Alliance's webinar on emerging therapies and clinical trials. Today, we stand at the confluence of a detailed understanding of the genetics of PKU the molecular processes underlying PKU and emerging medical technologies that are producing exciting new therapeutic approaches that hold the hope of improving the lives of PKU patients.
Today, the NPKUA is excited to present update on several of these emerging therapies and clinical trials. First step today, we'll hear from Dr. Ali Mohamadi at BioMarin; that will be followed by Dr. Albert Seymour at Homology Medicines; that will be followed by Dr. Jerry Vockley at University of Pittsburgh; and finally, we'll hear from Dr. Marja Puurunen at Synlogic.
Our mission -- one mission of the NPKUA is to provide reliable, unbiased information on emerging therapies and clinical trials for the treatment of PKU and to the PKU community. Presentation of information of emerging therapies and clinical trials does not imply endorsement or recommendation by
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
